



1 Fe

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jacques DUMAS et al. Confirmation No.: 8328
Serial No.: 09/458,014 Examiner: MITCHELL, Gregory W.
Filed: December 10, 1999 Group Art Unit: 1617
Title: INHIBITION OF P38 KINASE USING ACTIVITY SUBSTITUTED HETEROCYCLIC UREAS

REPLY


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated August 24, 2005, applicants elect with traverse group V directed to methods utilizing 1,3-oxazole. The traversal is on the basis that the PTO has not established that it would pose an undue burden to examine the full scope of the application. This is especially true with respect to groups V and II, both groups being directed to methods using oxazoles that are isomers of each other, where the terminology for searching would be the same. Applicants request the withdrawal of the restriction, and especially request that at least compounds of groups II and V be searched for the reasons stated above.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,


Csaba Henter, Reg. No. 50,908
Richard J. Traverso, Reg. No. 30,595
Attorneys for Applicants

MILLEN, WHITE, ZELANO &
BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER-0011-C01

Date: September 26, 2005